CNTB
Connect Biopharma Holdings Limited
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-41/100
Last price
0.95
▲ 0.04 (4.43%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.90
Prev close
0.91
Day high
0.97
Day low
0.89
Volume
665.16K
Market cap
$59.54M
P/E (TTM)
—
52W range
0.85 – 3.82
Day trading desk
Gap from prior close
-1.06%
Prior close 0.90
VWAP
0.93
+1.24% from price
Relative volume
0.18×
Quiet session
Session range
8.63%
0.89 – 0.97
Position in range
72%
Near session high
ATR (14D)
0.17
17.46% of price
Prior day high
0.98
PDH
Prior day low
0.85
PDL
Bid / ask spread
—
Quote not published
Session volume
704.59K
Avg 3.82M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-14.05%
-15.6%
1M
-50.50%
-51.6%
3M
-64.45%
-67.5%
6M
-64.05%
-78.6%
YTD
-66.47%
-80.1%
1Y
-40.91%
-56.2%
3Y
-5.45%
-86.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CNTB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
18.71M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 30, 26 | XANTHOPOULOS KLEANTHIS G Director |
STOCK | 5.00K | $0 | Direct |
| Jun 30, 26 | LIU JEAN I Director |
STOCK | 6.72K | $0 | Direct |
| Jun 30, 26 | XANTHOPOULOS KLEANTHIS G Director |
STOCK | 3.74K | $0 | Direct |
| May 29, 26 | HUANG JAMES Z Director |
BUY | 150.00K | $371.61K | Indirect |
| Mar 31, 26 | HUANG JAMES Z Director |
BUY | 1.16M | $3.04M | Indirect |
| Mar 31, 26 | LIU JEAN I Director |
STOCK | 5.06K | $0 | Direct |
| Mar 31, 26 | XANTHOPOULOS KLEANTHIS G Director |
STOCK | 2.82K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HUANG JAMES Z |
Director | — | Purchase |
LIU JEAN I |
Director | 11.78K | Stock Award(Grant) |
XANTHOPOULOS KLEANTHIS G |
Director | 91.55K | Stock Award(Grant) |
Fundamentals
Market cap$59.54M
Enterprise value$26.13M
Revenue (TTM)$2.95M
Gross profit$2.95M
EBITDA$-69.73M
Net income$-68.99M
EPS (TTM)$-1.19
Free cash flow$-34.71M
Total cash$31.49M
Total debt$596.00K
Book value / share$0.43
Shares outstanding62.97M
Float21.57M
Short % of float6.25%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.35
PEG ratio—
Price / sales—
Price / book2.21
EV / revenue8.85
EV / EBITDA-0.38
Gross margin100.00%
Operating margin-635.98%
Profit margin0.00%
Return on equity-140.51%
Return on assets-69.75%
Debt / equity2.22
Current ratio2.37
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $64.00K | $26.03M | $0 | $0 | -99.8% |
| Operating revenue | $64.00K | $26.03M | $0 | $0 | -99.8% |
| Research & development | $37.80M | $29.26M | $53.00M | $96.63M | +29.2% |
| Selling, general & admin | $20.34M | $19.23M | $16.05M | $20.81M | +5.8% |
| Total operating expense | $58.14M | $48.48M | $69.06M | $116.51M | +19.9% |
| Operating income | -$58.07M | -$22.45M | -$69.06M | -$116.51M | -158.7% |
| Net interest income | $2.27M | $4.45M | $5.22M | $1.52M | -49.1% |
| Pre-tax income | -$55.28M | -$15.40M | -$61.99M | -$117.79M | -258.9% |
| Tax provision | $197.00K | $223.00K | $120.00K | $298.00K | -11.7% |
| Net income | -$55.48M | -$15.63M | -$62.11M | -$118.09M | -255.0% |
| Net income to common | -$55.48M | -$15.63M | -$62.11M | -$118.09M | -255.0% |
| Basic EPS | -1.00 | -0.28 | -1.13 | -2.15 | -257.1% |
| Diluted EPS | -1.00 | -0.28 | -1.13 | -2.15 | -257.1% |
| EBIT | -$58.07M | -$22.45M | -$69.06M | -$117.77M | -158.7% |
| EBITDA | -$57.37M | -$21.79M | -$68.34M | -$116.74M | -163.3% |
| Basic shares | 55.66M | 55.21M | 55.07M | 55.04M | +0.8% |
| Diluted shares | 55.66M | 55.21M | 55.07M | 55.04M | +0.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $38.34M | $78.23M | $105.66M | $79.01M | -51.0% |
| Cash & short-term investments | $44.34M | $93.71M | $118.30M | $152.42M | -52.7% |
| Accounts receivable | $13.00K | $789.00K | $0 | — | -98.4% |
| Total current assets | $50.93M | $96.96M | $122.55M | $155.78M | -47.5% |
| Property, plant & equipment | $4.46M | $4.24M | $4.74M | $5.38M | +5.1% |
| Goodwill & intangibles | $45.00K | $53.00K | $62.00K | $3.17M | -15.1% |
| Total assets | $56.08M | $101.28M | $127.38M | $174.01M | -44.6% |
| Total current liabilities | $13.61M | $8.46M | $25.29M | $15.62M | +60.9% |
| Total debt | $690.00K | $178.00K | $465.00K | $431.00K | +287.6% |
| Total liabilities | $14.10M | $9.12M | $25.88M | $16.52M | +54.6% |
| Retained earnings | -$400.83M | -$345.36M | -$329.73M | -$479.84M | -16.1% |
| Shareholder equity | $41.98M | $92.17M | $101.50M | $157.49M | -54.5% |
| Working capital | $37.32M | $88.50M | $97.26M | $140.16M | -57.8% |
| Net tangible assets | $41.94M | $92.11M | $101.44M | $154.33M | -54.5% |
| Shares issued | 58.59M | 57.86M | 57.51M | 57.45M | +1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$55.48M | -$15.63M | -$62.11M | -$117.79M | — | -255.0% |
| Depreciation & amortisation | $704.00K | $660.00K | $720.00K | $1.03M | — | +6.7% |
| Stock-based compensation | $3.73M | $6.73M | $5.40M | $6.91M | — | -44.6% |
| Change in working capital | $580.00K | -$15.49M | $9.85M | $6.46M | — | +103.7% |
| Operating cash flow | -$51.21M | -$23.61M | -$47.74M | -$101.52M | — | -116.9% |
| Capital expenditure | -$434.00K | -$750.00K | -$81.00K | -$4.41M | — | +42.1% |
| Investing cash flow | $9.82M | -$3.45M | $74.98M | -$86.24M | — | +384.5% |
| Share buybacks | — | — | $0 | $0 | -$566.00K | — |
| Financing cash flow | $1.09M | $227.00K | $45.00K | -$85.00K | — | +381.5% |
| Free cash flow | -$51.64M | -$24.36M | -$47.82M | -$105.92M | — | -112.0% |
| End cash position | $38.34M | $78.23M | $105.66M | $79.01M | — | -51.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $2.77M | $169.00K | $0 | $16.00K | $48.00K | +1,537.9% |
| Operating revenue | $2.77M | $169.00K | $0 | $16.00K | $48.00K | +1,537.9% |
| Research & development | $16.27M | $15.03M | $11.28M | $11.11M | $8.77M | +8.3% |
| Selling, general & admin | $4.10M | $4.75M | $4.24M | $6.58M | $4.70M | -13.6% |
| Total operating expense | $20.37M | $19.78M | $15.53M | $17.69M | $13.47M | +3.0% |
| Operating income | -$17.60M | -$19.61M | -$15.53M | -$17.68M | -$13.42M | +10.2% |
| Net interest income | $313.00K | $260.00K | $384.00K | $545.00K | $619.00K | +20.4% |
| Pre-tax income | -$17.22M | -$19.35M | -$15.08M | -$17.14M | -$12.84M | +11.0% |
| Tax provision | $60.00K | $48.00K | $27.00K | $61.00K | $55.00K | +25.0% |
| Net income | -$17.28M | -$19.40M | -$15.11M | -$17.20M | -$12.90M | +10.9% |
| Net income to common | -$17.28M | -$19.40M | -$15.11M | -$17.20M | -$12.90M | +10.9% |
| Basic EPS | -0.27 | -0.34 | -0.27 | -0.31 | -0.23 | +20.6% |
| Diluted EPS | -0.27 | -0.34 | -0.27 | -0.31 | -0.23 | +20.6% |
| EBIT | -$17.60M | -$19.61M | -$15.53M | -$17.68M | -$13.42M | +10.2% |
| EBITDA | -$17.44M | -$19.44M | -$15.35M | -$17.50M | -$13.25M | +10.3% |
| Basic shares | 62.88M | 56.55M | 56.07M | 55.72M | 55.50M | +11.2% |
| Diluted shares | 62.88M | 56.55M | 56.07M | 55.72M | 55.50M | +11.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.02M | $46.03M | $38.34M | $37.84M | $40.63M | -41.3% |
| Cash & short-term investments | $31.49M | $46.03M | $44.34M | $54.78M | $71.77M | -31.6% |
| Accounts receivable | $2.94M | $0 | $13.00K | $17.00K | $0 | — |
| Total current assets | $38.62M | $55.02M | $50.93M | $62.60M | $77.76M | -29.8% |
| Property, plant & equipment | $4.16M | $4.36M | $4.46M | $4.67M | $4.88M | -4.5% |
| Goodwill & intangibles | $42.00K | $43.00K | $45.00K | $47.00K | $48.00K | -2.3% |
| Total assets | $43.47M | $60.07M | $56.08M | $67.36M | $82.72M | -27.6% |
| Total current liabilities | $16.30M | $17.05M | $13.61M | $11.43M | $10.74M | -4.4% |
| Total debt | $596.00K | $693.00K | $690.00K | $781.00K | $870.00K | -14.0% |
| Total liabilities | $16.61M | $17.44M | $14.10M | $11.99M | $11.38M | -4.8% |
| Retained earnings | -$437.52M | -$420.23M | -$400.83M | -$385.73M | -$368.53M | -4.1% |
| Shareholder equity | $26.86M | $42.62M | $41.98M | $55.37M | $71.34M | -37.0% |
| Working capital | $22.32M | $37.98M | $37.32M | $51.17M | $67.02M | -41.2% |
| Net tangible assets | $26.82M | $42.58M | $41.94M | $55.32M | $71.29M | -37.0% |
| Shares issued | 62.97M | 64.86M | 58.59M | 58.30M | 58.09M | -2.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$17.28M | -$19.40M | -$15.11M | -$17.20M | -$12.90M | — | +10.9% |
| Depreciation & amortisation | $161.00K | $164.00K | $181.00K | $179.00K | $171.00K | — | -1.8% |
| Stock-based compensation | $1.26M | $1.20M | $917.00K | $916.00K | $951.00K | — | +5.2% |
| Change in working capital | -$57.00K | $2.04M | $2.83M | -$1.13M | -$526.00K | — | -102.8% |
| Operating cash flow | -$15.92M | -$16.00M | -$11.25M | -$17.41M | -$12.59M | — | +0.5% |
| Capital expenditure | — | — | -$16.00K | -$34.00K | -$303.00K | -$81.00K | — |
| Investing cash flow | -$4.47M | $6.00M | $10.98M | $14.35M | $5.13M | — | -174.5% |
| Financing cash flow | $1.33M | $17.62M | $715.00K | $215.00K | $161.00K | — | -92.5% |
| Free cash flow | -$15.92M | -$16.00M | -$11.27M | -$17.44M | -$12.89M | — | +0.5% |
| End cash position | $27.02M | $46.03M | $38.34M | $37.84M | $40.63M | — | -41.3% |
Options analytics
Put / call volume
4.00
Put-heavy session
Put / call open interest
0.10
Positioning, not flow
Max pain
2.50
+164.4% from spot
ATM implied vol
381.3%
Nearest strike to spot
Skew (10% OTM)
+59.4%
Puts bid over calls
Call volume
3
Contracts, this expiry
Put volume
12
Contracts, this expiry
Heaviest call OI
2.50
1.67K contracts
Heaviest put OI
2.50
171 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.31 | -0.27 | +12.3% |
| Mar 2026 | -0.28 | — | — |
| Dec 2025 | -0.30 | -0.27 | +10.0% |
| Sep 2025 | -0.24 | -0.31 | -31.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.25 | 5 | $4.53M | +3,878.9% |
| Next quarter | -0.16 | 5 | $23.15M | 0.0% |
| Current year | -0.97 | 5 | $50.29M | +11,292.9% |
| Next year | -0.72 | 7 | $107.82M | +114.4% |
Analyst targets & ownership
Mean target$5.88
High target$9.00
Low target$4.00
Implied upside521.36%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy1 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders29.70%
Held by institutions56.13%
Institutions holding79
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.00
-5.52% from price
SMA 20
1.22
-22.56% from price
SMA 50
1.83
-48.40% from price
SMA 100
2.04
-53.68% from price
SMA 200
2.33
-59.39% from price
EMA 12
1.07
-11.36% from price
EMA 26
1.35
-29.97% from price
EMA 50
1.65
-42.77% from price
RSI (14)
32.1
Neutral
MACD (12,26,9)
-0.28
Hist 0.00
ATR (14)
0.17
17.46% of price
Realised vol 30D
179.6%
Annualised
Bollinger upper
1.89
20, 2σ
Bollinger lower
0.55
20, 2σ
50 / 200 cross
Death
1.83 vs 2.33
Trend bias
Below 200
-59.39%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.51
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
179.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-75.7%
Peak to trough
Max drawdown 5Y
-97.4%
Peak to trough
ATR 14
0.17
17.46% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
2.77M
Prior 1.82M
Change vs prior
+52.6%
Shorts adding
% of float
6.25%
Normal
% of shares out
4.41%
Against total outstanding
Days to cover
1.7
Liquid
Float
21.57M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 30, 26 | BTIG | MAINTAINED | Buy | Buy |
| Sep 22, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Sep 17, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 16, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Sep 15, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 9, 26 | Oppenheimer | INITIATED | — | Outperform |
| Jun 26, 26 | Piper Sandler | INITIATED | Neutral | Overweight |
| Jun 25, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 26, 26 | Canaccord Genuity | INITIATED | — | Buy |
| May 21, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Apr 1, 26 | BTIG | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-30
Corporate Changes & Voting Matters
8-K · 2026-09-15
Periodic Financial Reports
10-Q · 2026-08-12
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-28
Offering Registrations
F-3 · 2026-05-15
Periodic Financial Reports
10-Q · 2026-05-12
Corporate Changes & Voting Matters
8-K · 2026-04-23
Corporate Changes & Voting Matters
8-K · 2026-03-31
Headlines
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
MarketBeat · 3d ago
Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program
InvestorsHub · 7d ago
BC-Most Active Stocks
Associated Press · 7d ago
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
GlobeNewswire · 7d ago
Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?
Insider Monkey · 15d ago
Oppenheimer Adjusts Price Target on Connect Biopharma to $5 From $8, Keeps Outperform Rating
MT Newswires · 15d ago
Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance
InvestorsHub · 22d ago
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
GlobeNewswire · 22d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.